Compare Ginkgo Bioworks Holdings Inc (DNA) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Invesco Ltd. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.07 (market cap $590.53M), while Invesco Ltd. trades at $30.22 (market cap $12.74B). The key difference: Invesco Ltd. is far larger — about 21.6× Ginkgo Bioworks Holdings Inc's market cap, and Invesco Ltd. pays a 2.99% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | IVZ | |
|---|---|---|
Market Cap | $590.53M | $12.74B |
Sector | Health | Financials |
52-Week High | $16.14 | $29.44 |
52-Week Low | $5.48 | $16.74 |
Enterprise Value | $627.78M | $22.98B |
Dividend Yield | — | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Invesco (IVZ) trades at $28.4, down 2.0% on the day, with a bullish technical signal driven by moving averages. The company reported mixed earnings, beating in Q3 and Q4 2025 but missing in Q1 2026, while revenue grew to $6.38B in 2025. Analyst consensus is a Buy with a $30.50 price target, and recent news highlights upgrades and strong momentum.
The outlook is cautiously optimistic given analyst support and improving cash flow, but risks include negative net income margins and competitive pressures in asset management. Upside hinges on earnings recovery and AUM growth, while macroeconomic volatility remains a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
